17 March 2025
: Case report 
Enzyme Replacement and Immunosuppression in Heart Transplant Recipients with Fabry Cardiomyopathy: A 7-Year Case Study
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease
Katarzyna Muras-Szwedziak
ABCDEF 1, Maciej Wójcik ABCDEF 2, Olga Wojtyczka ABCDEF 2*, Krzysztof Kaczmarek ABCDEF 3
DOI: 10.12659/AJCR.945873
Am J Case Rep 2025; 26:e945873
Table 1. Literature review of heart transplantations in Fabry disease patients.
| Author and year of publication | Sex | Age of organ recipient | Results and complications of heart transplant (HT) | Medication (ERT, immunosuppressives) | Type of transplantation (single, combined, transplant after transplant) |
|---|---|---|---|---|---|
| Verocai et al, 2010 []16 | Female | 53 | 14 years after HT – no signs of FD or rejection in endomyocardial biopsy | Alpha-agalsidase, sirolimus, tacrolimus, mofetil mycophenolate | Heart transplant |
| Kyem et al, 2023 []17 | Male | 62 | 13 years after HT – no signs of abnormal heart function | Triple immunosuppression therapy, alpha-agalsidase | Kidney after heart transplant |
| Rajagopalan et al, 2019 []18 | Male | 62 | 7 years after HT – no signs of abnormal heart function | Beta-agalsidase, no data about the type of immunosuppressives | Combined heart and kidney transplant |
| Karras et al, 2008 []19 | Male | 42 | 12 months after HT – no signs of FD or rejection in endomyocardial biopsy | Alpha-agalsidase, no data about the type of immunosuppressives | Combined heart and kidney transplant |
| Tran et al, 2017 []20 | Male | 49 | 4 years after HT – no signs of abnormal heart function | Shock after administration of both alpha and beta-agalsidase, mycophenolate mofetil, cyclosporine, prednisone | Combined heart and kidney transplant |
| Tran et al, 2017 []20 | Male | 42 | 9 years after HT – no signs of abnormal heart function | Alpha-agalsidase, mycophenolate mofetil, cyclosporin replaced by tacrolimus (renal failure), prednisone | Combined heart and kidney transplant |